This study represents the first head-to-head trial comparing the effects of two biologics in axial spondyloarthritis, in this case in patients at high risk for radiographic progression.
Those who had had inflammatory bowel disease for less than 5 years and those taking adalimumab, as opposed to another TNFi, had higher likelihood of reaching axial spondyloarthritis remission.